Increased expression of the oncogenic KLF6-SV1 transcript in human glioblastoma

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 8, 2010, Pages 1167-1170

  Tchirkov, Andrei ^a,b,c   Sapin, Vincent ^a   Marceau, Geoffroy ^a   Chautard, Emmanuel ^a,c   Narla, Goutham ^d   Veronese, Lauren ^b   Friedman, Scott ^d   Khalil, Toufic ^b   Vago, Philippe ^b   Kemeny, Jean Louis ^b   Verrelle, Pierre ^a,c  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^c CENTRE JEAN PERRIN   (France)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

glioblastoma multiforme; gliomas; KLF6 SV1; Kr ppel like factor (KLF)6

Indexed keywords

CARMUSTINE; KRUPPEL LIKE FACTOR 6; MESSENGER RNA; TEMOZOLOMIDE;

ARTICLE; ASTROCYTOMA; DRUG MEGADOSE; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; WILD TYPE;

ADULT; ALTERNATIVE SPLICING; BRAIN NEOPLASMS; CARCINOGENS; FEMALE; GENE EXPRESSION REGULATION; GLIOBLASTOMA; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER;

EID: 77955448865     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.219     Document Type: Article

References (22)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et. al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et. al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
3. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, et. al. Genetic pathways to glioblastoma: a populationbased study. Cancer Res 2004;64:6892-6899
4. Kaczynski J, Cook T, Urrutia R. Sp1- and Kruppel-like transcription factors. Genome Biol 2003;4:206.
5. Chiambaretta F, Nakamura H, De Graeve F, Sakai H, Marceau G, Maruyama Y, et. al. Kruppel-like factor 6 (KLF6) affects the promoter activity of the alpha1-proteinase inhibitor gene. Invest Ophthalmol Vis Sci 2006;47:582-590
6. Slavin D, Sapin V, Lopez-Diaz F, Jacquemin P, Koritschoner N, Dastugue B, et. al. The Kruppel-like core promoter binding protein gene is primarily expressed in placenta during mouse development. Biol Reprod 1999;61:1586-1591
7. Jeng YM, Hsu HC. KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int J Cancer 2003;105:625-629
8. Kimmelman AC, Qiao RF, Narla G, Banno A, Lau N, Bos PD, et. al. Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. Oncogene 2004;23: 5077-5083
9. Kohler B, Wolter M, Blaschke B, Reifenberger G. Absence of mutations in the putative tumor suppressor gene KLF6 in glioblastomas and meningiomas. Int J Cancer 2004;111:644-645
10. Montanini L, Bissola L, Finocchiaro G. KLF6 is not the major target of chromosome 10p losses in glioblastomas. Int J Cancer 2004;111:640-641
11. Camacho-Vanegas O, Narla G, Teixeira MS, DiFeo A, Misra A, Singh G, et. al. Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. Int J Cancer 2007;121:1390-1395
12. DiFeo A, Feld L, Rodriguez E, Wang C, Beer DG, Martignetti JA, et. al. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response. Cancer Res 2008;68:965-970
13. Hartel M, Narla G, Wente MN, Giese NA, Martignoni ME, Martignetti JA, et. al. Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer. Eur J Cancer 2008;44: 1895-1903
14. Narla G, DiFeo A, Yao S, Banno A, Hod E, Reeves HL, et. al. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res 2005;65:5761-5768
15. Tchirkov A, Rolhion C, Kemeny JL, Irthum B, Puget S, Khalil T, et. al. Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas. Br J Cancer 2003;88:516-520
16. Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, et. al. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J Clin Invest 2008;118:2711-2721
17. Buonamici S, Ottaviani E, Testoni N, Montefusco V, Visani G, Bonifazi F, et. al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002;99:443-449
18. DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL, et. al. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res 2006;12:3730-3739
19. Kwiatkowski F, Girard M, Hacene K, Berlie J. wSem: a suitable statistical software adapted for research in oncologyx. Bull Cancer 2000;87:715-721
20. Fackental JD, Godley LA. Aberrant RNA splicing and its functional consequences in cancer cell. Dis Model Mech 2009;1: 37-42.
21. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 2007;8:349-357
22. Difeo A, Matignetti JA, Narla G. The role of KLF6 and its splice variants in cancer therapy. Drug Resist Updat 2009;12: 1-7.